Buyers Say Pfizer Falsely Labeled Heartburn Drug As Safe

By Ryan Boysen (January 2, 2020, 8:01 PM EST) -- A New Jersey woman has hit Pfizer Inc. with a proposed class action over the recently recalled heartburn medication Zantac, alleging that the product was worthless because it has been found to contain a potent cancer-causing chemical.

In a complaint filed Thursday, named plaintiff Dana Viola said Pfizer, which received approval from the U.S. Food and Drug Administration for an over-the-counter version of Zantac in 2004 and was the drug's primary manufacturer for the next several years, should have known the product was contaminated with N-nitrosodimethylamine, or NDMA.

NDMA is a "carcinogenic and liver-damaging impurity," Viola said, that has previously been...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!